# ICOTYDE

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/icotyde
Canonical HTML page: https://gethealthbrief.com/entity/icotyde

## Recent coverage (1 stories)

### How Protagonist’s $620M Cash Runway Through 2028 Supports 2 Peptide Drug Launches
2026-06-14 01:25:03 · Sentiment: Bullish · Impact: 7/10 · Sources: 2

Protagonist Therapeutics' shift to a royalty-driven, capital-light model ensures sustained funding for two near-term peptide drug launches. With over $620 million in cash, the company is poised to deliver new treatment options while minimizing financial risk.
Full story: https://gethealthbrief.com/story/protagonist-therapeutics-620m-cash-runway-2-drug-launches-health

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.